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Statin-mediated cholesterol lowering improves clinical outcomes. But despite this, many individuals demonstrate atheroma progression, 1 and many such patients experience further cardiovascular events. Randomized clinical trials employing the best contemporary medical therapies demonstrate, at most, relative risk reductions of the order of 30-40%. This highlights a significant degree of residual cardiovascular risk experienced by a large proportion of individuals prescribed statins for secondary clinical prevention. 2 Accordingly, there is a need to identify novel targets and therapeutic strategies to effectively combat this residual risk.
Multiple avenues of research implicate inflammation as a factor involved in the initiation, progression and instability of atherosclerotic plaques. 3, 4 Elevations of serum inflammatory biomarkers consistently associate with the risk of experiencing a cardiovascular event. 5, 6 Creactive protein (CRP), in particular, has been extensively investigated, and the prognostic utility of baseline CRP levels is now considered by some, to be equivalent to that of serum cholesterol levels. 7, 8 While many benefits of statins are attributed to cholesterol lowering, both coronary atheroma regression 9 and clinical event reductions 10 have also been shown independently to correlate with statin-mediated CRP lowering. Yet there remains an ongoing debate as to whether the effects of statin-mediated CRP lowering are simply a function of parallel changes in lowdensity lipoprotein cholesterol (LDL-C), or follow a separate mechanistic pathway. The prognostic benefit of CRP in statin-treated patients who achieve LDL-C levels <70 mg/dL, is uncertain.
SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect of
Rosuvastatin Versus Atorvastatin; ClinicalTrials.gov number, NCT000620542) was the first head-to-head comparison of the anti-atherosclerotic effect of two potent statin agents, each prescribed at their maximal approved dose, on coronary atherosclerosis progression. 12 Treatment biomarkers consistently associate with the risk of experiencing a cardiovascular e e even e e t t. . 5 , 5, 5 6 6 6 C C C--eactive protein (CRP), in particular, has been extensively investigated, and the prognostic utility of f b b bas as asel el elin in ine e e CR CR C P P le le lev vels is now considered by som me me, , to be equivale e ent n n to o th th that a of serum cholesterol e eve e els l . 7, 8 Whi ile le m m man any y be be ene ne nefi fi its ts ts o of f st st s a a ati tins ns are e at t ttrib bu but ted to to o c cho ho h le les st t ter r rol l lo lo low we eri ring ng ng, , bo bo oth th th c co or ron on onar ary y y with both agents was associated with regression of coronary atheroma, although there was no significant difference between the two groups in the primary efficacy end point of change in percent atheroma volume (PAV); nor was there a difference in safety or clinical event rates between each treatment group. The primary objective of this prespecified post hoc analysis was to examine the prognostic effect of changes in CRP levels on both coronary atheroma progression and major adverse cardiovascular events (MACE) in patients following 24 months of maximally intensive statin therapy.
Methods

Patient selection
The design of SATURN has been previously described. 13 Briefly, patients with angiographically demonstrable coronary disease and LDL-C <116 mg/dL following a 2-week treatment period with atorvastatin 40 mg or rosuvastatin 20 mg daily were re-randomized and treated for 24-months with atorvastatin 80 mg or rosuvastatin 40 mg daily. Subjects underwent intravascular ultrasound (IVUS) imaging of a coronary artery at baseline and after 104 weeks of treatment.
Acquisition and analysis of intravascular coronary imaging
The presence of at least a single lumen stenosis of >20% angiographic diameter stenosis severity in an epicardial coronary artery at the time of a clinically indicated coronary angiogram was necessary for enrolment eligibility. IVUS was performed at baseline in a single, native coronary artery with no lumen stenosis of >50% severity, which had not undergone revascularization and was not considered to be the culprit vessel of a prior myocardial infarction (MI). Images were screened by the Atherosclerosis Imaging Core Laboratory of the Cleveland Clinic Center for
Clinical Research for quality, and those patients whose baseline imaging met these requirements,
Patient selection
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14 Change in plaque burden was calculated as the PAV at 104 weeks minus the corresponding PAV at baseline. Plaque regression was defined as any decrease in PAV from baseline. The post-hoc analyses presented here pooled results from both treatment groups; as in SATURN, they did not differ in the primary efficacy endpoint of the change in PAV from baseline, and the average ontreatment CRP levels were not different between the rosuvastatin-and atorvastatin-treated groups.
Statistical analysis
Continuous variables were reported as mean ± SD if normally distributed and as median (interquartile range) if non-normally distributed. Demographics, baseline clinical characteristics, follow-up medications, baseline ultrasonic and laboratory biochemical data were compared between those who had an increase in average on-treatment CRP levels from baseline, against those whose on-treatment CRP levels did not increase. Two-sample t-tests were used for normally distributed continuous variables, Wilcoxon rank-sum tests for non-normally distributed continuous variables, and chi-square tests for categorical variables. Serial changes in IVUS measurements were analyzed by analysis of variance (ANOVA), adjusting for their baseline counterparts, and were reported as least-squares mean ± SE. Given the significant difference observed for change in PAV between those whose CRP increased versus those whose CRP did differ in the primary efficacy endpoint of the change in PAV from baseline, and d t th the e e av v ver er erag ag age e e on onreatment CRP levels were not different between the rosuvastatin-and atorvastatin-treated gr grou ou ups ps ps. .
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These survival analyses applied a cut-off date of 24 months, and used the time to the first occurrence of MACE for analysis. Patients with no MACE by 24 months were censored at this time point. The MACE analysis included all patients who were randomized according to the treatment regimen with on-treatment CRP records (n=1263). All remaining analyses used the modified intent-to-treat population, which included all patients with a baseline and follow-up IVUS measurement, as well as on-treatment CRP levels (n=985). A 2-sided P-value of <0.05
was considered statistically significant. All analyses were performed using SAS software version 9.2 (SAS Institute, Cary, North Carolina). Table 1 shows the baseline demographics, clinical characteristics and concomitant medications of patients who had evaluable CRP levels, stratified according to whether CRP levels increased (n=364) or did not increase (n=621) from baseline. The mean age of the studied population was 57.6±8.5 years, with a male preponderance (73.4%). The 2 patient groups did not differ at baseline in their cardiovascular risk factor profile, mode of clinical presentation or concomitant medications. Table 2 shows baseline, follow-up and changes of lipids and CRP levels. During the course of the study, LDL-C decreased by 44% from 120.3±28 mg/dL to 65.9±23 mg/dL, high-density lipoprotein cholesterol (HDL-C) increased by 12% from 44.9±11mg/dL to 49.4±12 mg/dL, and 9.2 (SAS Institute, Cary, North Carolina).
Results
Patient characteristics
Laboratory measurements
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Atheroma burden and vascular dimensions
Association of changes in CRP levels with changes in lipid parameters
After controlling for baseline CRP and lipid values, the change in CRP correlated weakly but significantly with changes in LDL-C (r=0.07, p=0.02), non-HDL-C (r=0.1, p=0.001), Table 3 describes the baseline and change in IVUS measurements in patients st tra ra ati ifi fi f ed ed d a a acc cc ccor or ord ding o changes in CRP levels. In the overall population, PAV decreased by -1.23±0.09% (p<0.001),
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Multivariable analysis of factors associated with any reduction in CRP from baseline
CRP levels and MACE
Many consider statin-mediated CRP lowering, and the corresponding anti-inflammatory effects, to result from the change in LDL-C levels. 20 As such, the relevance of CRP to clinical outcomes in statin-treated patients has engendered some controversy. In REVERSAL, correlation analysis revealed that reductions in atherogenic lipoprotein levels correlated weakly with CRP reductions (change in LDL-C vs. change in CRP: r = 0.13, p=0.005), with no correlations between changes in LDL-C and CRP noted in each treatment group alone. 9 Changes in LDL-C correlated negligibly with an individual's change in CRP in numerous large outcome trials including the Cholesterol and Recurrent Events (CARE) trial, 21 PROVE-IT, 22 and
Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin (JUPITER). 17 In the overall SATURN population, we similarly report only a weak correlation between changes in CRP and changes in LDL-C (r = 0.07, p=0.02). Prior observations also show statin-mediated CRP lowering noted to occur rapidly and independently of LDL-C lowering. 23 The consistent independent variation of reductions in LDL-C and CRP in evolution.
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In the present analysis, on-treatment CRP levels associated with MACE, including a trend for an association with hard MACE. It is important to note that our findings do not lend support for a causal role of CRP in the genesis of cardiovascular events. 24 Rather, our findings add to the considerable evidence supporting the prognostic role of persistent inflammation, 25 even in individuals with coronary artery disease treated optimally with potent statin regimens and very-low achieved LDL-C levels. These findings also have important implications for the quest to develop novel therapeutic strategies specifically targeting inflammation, to possibly achieve added risk reduction in those patients already optimized with maximally intensive statin therapy. Furthermore, the observed trend towards a stepwise relationship between on-treatment CRP levels and risk of MACE suggests that therapies designed to lower inflammation could be titrated. 26 This implication may ultimately depend upon the magnitude of CRP lowering required to achieve net clinical benefit.
This analysis has limitations. Our findings are a prespecified post-hoc analysis of a clinical trial that failed to meet its primary efficacy endpoint of elucidating differences in coronary atheroma volume progression between the 2 potent statin regimens. However, the treatment assignments in SATURN represent the most intensive statin regimens currently available, and SATURN demonstrated no differences in the magnitude of PAV regression (primary efficacy endpoint), CRP-lowering capabilities or clinical outcome between these 2 agents. Nevertheless, these results should be considered as hypothesis-generating. Furthermore, other unmeasured confounding variables could have influenced systemic levels of inflammation, biasing our results. We also cannot attribute plaque and vessel responses measured on IVUS achieve added risk reduction in those patients already optimized with maximally y in inte te t ns ns siv iv ive e e st st stat atin herapy. Furthermore, the observed trend towards a stepwise relationship between on-treatment CR CR RP P P le le leve vels ls ls a an n nd r r ris is isk k of MACE suggests that thera ra rapi pies designed to o l low wer er er i inf n lammation could be i i itra at ated. 26 This s im im imp p plic ica at a io io on n n ma ma may y y ul ul lti ti t ma ma mate tely d However, similar to the deleterious effects of systemic inflammation on the arterial wall, atherosclerosis is a systemic disease, and common to most atherosclerosis imaging trials, the imaged vessel simply represents a snapshot of the serial response of the arterial vasculature to such conditions.
In conclusion, in patients with coronary artery disease, most of whom achieved LDL-C levels below 70 mg/dL (average 65.9 mg/dL) following 2 years of maximally intensive statin therapy; over one third of patients did not experience a fall in on-treatment CRP from baseline.
These patients demonstrated less coronary atheroma regression than those with decreasing CRP levels. On-treatment CRP, but not on-treatment LDL-C levels, independently associated with MACE and displayed a strong trend towards associating with hard MACE. These findings suggest that systemic inflammation may contribute to cardiovascular risk in optimally treated individuals, and underscores the importance of clinical trials that will specifically test the inflammatory hypothesis of atherothrombosis. Baseline and follow-up values are reported as mean ± SD, and change values are reported as leas ast t t sq sq squa ua are re res s s me me mean an an ± ± SE. †P value reflects comparisons between groups dichotomized according to change in CRP level
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